Evidence map›Paper›PMID 36505849›Full record

ArticleFrontiers in oncology2022

A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer.

Ying Jin, Jin Li, Lin Shen, Jianming Xu, Yanqiao Zhang, Jingdong Zhang, Hongming Pan, Xiujuan Qu, Yamin Chen, Qiang Zhang and 3 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02314819 (A Randomized, Double-blind and Placebo-controlled Phase III Trial Comparing Fruquintinib Efficacy and Safety vs Best Support Care), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02314819 phase3completednot on this map

A Randomized, Double-blind and Placebo-controlled Phase III Trial Comparing Fruquintinib Efficacy and Safety vs Best Support Care (BSC) in Advanced Colorectal Cancer Patients Who Have Failed at Least Second Lines of Chemotherapies

TypeinterventionalSponsorHutchison Medipharma LimitedRan2014 to 2017Enrolled416ConditionsColorectal CancerArmsfruquintinib, placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ying JinDepartment of Medical Oncology, Sun Yat-Sen University Cancer Centre, Guangzhou, China.
Jin LiDepartment of Medical Oncology, Shanghai Oriental Hospital Affiliated Tongji University East Hospital, Shanghai, China.
Lin ShenDepartment of Gastrointestinal Oncology, Beijing Cancer Hospital, Beijing, China.
Jianming XuDepartment of Medical Oncology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China.
Yanqiao ZhangDepartment of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China.
Jingdong ZhangDepartment of Gastroenterology, Liaoning Cancer Hospital and Institute, Shenyang, China.
Hongming PanDepartment of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Xiujuan QuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Yamin ChenDepartment of Medical Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Qiang ZhangEli Lilly and Company, Lilly China Drug Development and Medical Affairs Centre, Shanghai, China.
Jinnan LiEli Lilly and Company, Lilly China Drug Development and Medical Affairs Centre, Shanghai, China.
Miaomiao SunEli Lilly and Company, Lilly China Drug Development and Medical Affairs Centre, Shanghai, China.
Shukui QinDepartment of Medical Oncology, People's Liberation Army (PLA) Cancer Centre of Jinling Hospital, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The objective of this study was to assess the comparative efficacy in third-line setting for metastatic CRC (mCRC) patients using matched population of FRESCO trial with fruquintinib and real-world data with other TKIs. Materials and methods: The arm of fruquintinib from the FRESCO phase III trial (NCT02314819) included the data of patients with metastatic CRC that progressed after at least two lines of chemotherapy and received fruquintinib treatment. An external control arm was constructed using real-world data (RWD) of patients who received other TKIs based on key eligibility criteria of FRESCO. The baseline characteristics of two arms was balanced by propensity score matching (PSM). The Kaplan-Meier method and Cox proportional hazard model was used to evaluate progression free survival (PFS) and to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), respectively. Results: Overall, 128 patients were successfully matched by PSM in each, fruquintinib and other TKIs group. The patients in fruquintinib group showed significant increase in median PFS than other TKIs (3.71 Conclusion: With the approach of establishing the external control arm from RWD, this study has demonstrated that treatment with fruquintinib significantly prolonged PFS as compared to other TKIs in patients as third-line mCRC treatment.

Indexed as

FRESCOfruquintinibmetastatic colorectal cancerprogression free survivalreal-world datatyrosine kinase inhibitors

Identifiers

PMID36505849
PMCPMC9730021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.